Meeting
2022 ASCO Annual Meeting
Final progression-free survival analysis of phase II study with the combination therapy of DFP-14323, protease inhibitor, and low-dose afatinib as first-line therapy for common EGFR mutation–positive NSCLC.
Authors
Hiroshige Yoshioka
Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan
Hiroshige Yoshioka , Masahide Mori , Nobuyuki Katakami , Toshihide Yokoyama , Hiroyasu Kaneda , Hirotaka Matsumoto , Toru Kumagai , Kouji Yamamoto , Cheng-long Huang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
UMIN000033062
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9111)
DOI
10.1200/JCO.2022.40.16_suppl.9111
Abstract #
9111
Poster Bd #
97
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Interim results of a phase II single arm trial combining afatinib with cetuximab in patients with EGFRex20ins positive NSCLC.
First Author: Bianca van Veggel
Poster
2019 ASCO Annual Meeting
Phase II randomized trial of afatinib with or without cetuximab as first-line treatment for EGFR mutated non-small cell lung cancer (NSCLC) patients (IFCT-1503 ACE-Lung).
First Author: Alexis B. Cortot
Poster
2016 ASCO Annual Meeting
First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).
First Author: Vera Hirsh
Poster
2023 ASCO Annual Meeting
Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC (UNICORN): A phase 2 study.
First Author: Yusuke Okuma